The objective of this RFI is to solicit feedback from industry, academia, and other stakeholders to assist BARDA in understanding existing process bottlenecks and to identify technologies, capabilities, and potential partnerships that can substantially improve the speed, scalability, and adaptability of antibody (or other protein/peptide binders) development for diagnostic applications, particularly for unknown biothreats or emerging pathogens.

Respondents do not have to be a member of the RRPV consortium to submit a response for this RFI; however, they must be a member of the consortium to respond to any future request for project proposals (RPP) for this requirement.

RFI submissions should be emailed to rrpv@ati.org by the deadline listed in the RFI. Late submissions will not be considered.

Original RFI Release:

Issued: 31 October 2025

Due: 4 December 2025, 1pm EST